Characterization of new users of cilostazol in the UK, Spain, Sweden, and Germany.

ABSTRACT:

Purpose

To describe the characteristics of new users of cilostazol in Europe with the aim to support the evaluation of its benefit/risk as used in regular clinical practice before the implementation of labeling changes recommended by the European Medicines Agency.

Methods

New users of cilostazol were identified in populations enrolled in five European health automated databases in the UK (The Health Improvement Network [THIN]), Spain (EpiChron cohort and Information System for the Improvement of Research in Primary Care [SIDIAP]), Sweden (National Registers), and Germany (German Pharmacoepidemiological Research Database [GePaRD]) between 2002 and 2012. New users were characterized according to the prevalence of cardiovascular disease and other comorbidities, concurrent use o

SUBMITTER: Castellsague J 

PROVIDER: S-EPMC5484386 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature